Azitra, Inc. (AZTR)
| Market Cap | 1.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.96M |
| Shares Out | 10.74M |
| EPS (ttm) | -2.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 986,541 |
| Open | 0.180 |
| Previous Close | 0.182 |
| Day's Range | 0.174 - 0.181 |
| 52-Week Range | 0.155 - 2.664 |
| Beta | -1.59 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+2,185.71%) |
| Earnings Date | Feb 27, 2026 |
About AZTR
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epider... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AZTR stock is "Strong Buy" and the 12-month stock price target is $4.0.
News
Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates
BRANFORD, Conn., Feb. 27, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermat...
Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestones BRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- Azit...
Azitra, Inc. to Present at BIO Investment & Growth Summit
BRANFORD, Conn., Feb. 19, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, toda...
Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
BRANFORD, Conn., Feb. 6, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...
Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
BRANFORD, Conn., Jan. 7, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermato...
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
BRANFORD, Conn. , Dec. 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
BRANFORD, Conn. , Nov. 24, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision derma...
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
BRANFORD, Conn. , Nov. 12, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision derma...
Azitra, Inc. Addresses False Report Regarding Sale of Securities
BRANFORD, Conn. , Nov. 7, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, toda...
Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris
ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis vulgaris Preclinical data show production of active, functional filaggrin delivered thro...
Azitra Receives Notice of Non-Compliance from NYSE American
BRANFORD, Conn. , Oct. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, toda...
Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BRANFORD, Conn. , Sept. 4, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash
BRANFORD, Conn., Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermat...
Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole—EpicQuest, Zoom, Azitra Stocks In Focus
U.S. stock futures rose on Friday following Thursday's declines. Futures of major benchmark indices were higher.
Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates
BRANFORD, Conn. , Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision derma...
Azitra, Inc. Announces Reverse Stock Split
Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025 BRANFORD, Conn. , Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical comp...
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site Trial is 50% enrolled; six patients have received ATR12-35...
Azitra, Inc. Announces Presentation at the 2025 BIO International Convention
BRANFORD, Conn. , June 10, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
BRANFORD, Conn. , May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, toda...
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash
Azitra plans to dose first patient in a Phase 1/2 trial in the first half of 2025 for its precision dermatology candidate ATR04-484, designed for the treatment of EGFR inhibitor-associated rash BRANFO...
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...
Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025
Azitra is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 BRANFORD, Conn., April 25, 2025 /PRNews...
Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
BRANFORD, Conn. , April 24, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, to...
Azitra to Present at Microbiome Times Partnering Forum
BRANFORD, Conn. , March 12, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, to...
Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates
BRANFORD, Conn. , Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...